These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

371 related items for PubMed ID: 15305228

  • 21. Angiotensin-converting enzyme inhibition and calcium channel blockade both normalize early hyperfiltration in experimental diabetes, but only the former prevents late renal structural damage.
    Perico N, Amuchastegui CS, Malanchini B, Bertani T, Remuzzi G.
    Exp Nephrol; 1994; 2(4):220-8. PubMed ID: 8069658
    [Abstract] [Full Text] [Related]

  • 22. Tumor necrosis factor-alpha gene expression in diabetic nephropathy: relationship with urinary albumin excretion and effect of angiotensin-converting enzyme inhibition.
    Navarro JF, Milena FJ, Mora C, León C, Claverie F, Flores C, García J.
    Kidney Int Suppl; 2005 Dec; (99):S98-102. PubMed ID: 16336586
    [Abstract] [Full Text] [Related]

  • 23. Effects of angiotensin II receptor antagonist olmesartan on renal hemodynamic variables and vascular structural properties in streptozotocin-induced diabetic rats.
    Song HF, Chen JF, Sun NL, Li HW.
    Chin Med J (Engl); 2011 Feb; 124(4):562-7. PubMed ID: 21362282
    [Abstract] [Full Text] [Related]

  • 24. Angiotensin II blockade prevents hyperglycemia-induced activation of JAK and STAT proteins in diabetic rat kidney glomeruli.
    Banes AK, Shaw S, Jenkins J, Redd H, Amiri F, Pollock DM, Marrero MB.
    Am J Physiol Renal Physiol; 2004 Apr; 286(4):F653-9. PubMed ID: 14678947
    [Abstract] [Full Text] [Related]

  • 25. Regional hemodynamic effects of candesartan cilexetil (TCV-116), an angiotensin II AT1-receptor antagonist, in conscious spontaneously hypertensive rats.
    Kanagawa R, Wada T, Sanada T, Ojima M, Inada Y.
    Jpn J Pharmacol; 1997 Mar; 73(3):185-90. PubMed ID: 9127812
    [Abstract] [Full Text] [Related]

  • 26. Effects of the combination of an angiotensin II antagonist with an HMG-CoA reductase inhibitor in experimental diabetes.
    Qin J, Zhang Z, Liu J, Sun L, Hu L, Cooper ME, Cao Z.
    Kidney Int; 2003 Aug; 64(2):565-71. PubMed ID: 12846751
    [Abstract] [Full Text] [Related]

  • 27. Spironolactone exhibits direct renoprotective effects and inhibits renal renin-angiotensin-aldosterone system in diabetic rats.
    Taira M, Toba H, Murakami M, Iga I, Serizawa R, Murata S, Kobara M, Nakata T.
    Eur J Pharmacol; 2008 Jul 28; 589(1-3):264-71. PubMed ID: 18582458
    [Abstract] [Full Text] [Related]

  • 28. Renoprotective effects of combination of angiotensin converting enzyme inhibitor with mycophenolate mofetil in diabetic rats.
    Wu YG, Lin H, Qian H, Zhao M, Qi XM, Wu GZ, Lin ST.
    Inflamm Res; 2006 May 28; 55(5):192-9. PubMed ID: 16830106
    [Abstract] [Full Text] [Related]

  • 29. Protective effects of candesartan cilexetil (TCV-116) against stroke, kidney dysfunction and cardiac hypertrophy in stroke-prone spontaneously hypertensive rats.
    Inada Y, Wada T, Ojima M, Sanada T, Shibouta Y, Kanagawa R, Ishimura Y, Fujisawa Y, Nishikawa K.
    Clin Exp Hypertens; 1997 Oct 28; 19(7):1079-99. PubMed ID: 9310205
    [Abstract] [Full Text] [Related]

  • 30. Role of angiotensin II in cerebrovascular and renal damage in deoxycorticosterone acetate-salt hypertensive rats.
    Wada T, Kanagawa R, Ishimura Y, Inada Y, Nishikawa K.
    J Hypertens; 1995 Jan 28; 13(1):113-22. PubMed ID: 7759841
    [Abstract] [Full Text] [Related]

  • 31. Involvement of angiotensin II in progression of renal injury in rats with genetic non-insulin-dependent diabetes mellitus (Wistar fatty rats).
    Noda M, Matsuo T, Nagano-Tsuge H, Ohta M, Sekiguchi M, Shibouta Y, Naka T, Imura Y.
    Jpn J Pharmacol; 2001 Apr 28; 85(4):416-22. PubMed ID: 11388646
    [Abstract] [Full Text] [Related]

  • 32. Renal responses to angiotensin receptor antagonist and angiotensin-converting enzyme inhibitor in partially nephrectomized spontaneously hypertensive rats.
    Okada H, Suzuki H, Kanno Y, Ikenaga H, Saruta T.
    J Cardiovasc Pharmacol; 1995 Oct 28; 26(4):564-9. PubMed ID: 8569216
    [Abstract] [Full Text] [Related]

  • 33. Enalapril improves vascular and cardiac function in streptozotocin-diabetic rats.
    Crespo MJ, Dunbar DC.
    Cell Mol Biol (Noisy-le-grand); 2003 Dec 28; 49(8):1311-8. PubMed ID: 14984003
    [Abstract] [Full Text] [Related]

  • 34. [The effect of temocapril, an angiotensin-converting enzyme inhibitor with preferential biliary excretion, on experimental diabetic nephropathy].
    Yanagisawa Y.
    Nihon Jinzo Gakkai Shi; 1994 Oct 28; 36(10):1095-102. PubMed ID: 7815741
    [Abstract] [Full Text] [Related]

  • 35. Effects of candesartan cilexetil and enalapril on inflammatory markers of atherosclerosis in hypertensive patients with non-insulin-dependent diabetes mellitus.
    Rosei EA, Rizzoni D, Muiesan ML, Sleiman I, Salvetti M, Monteduro C, Porteri E, CENTRO (CandEsartaN on aTherosclerotic Risk factors) study investigators.
    J Hypertens; 2005 Feb 28; 23(2):435-44. PubMed ID: 15662233
    [Abstract] [Full Text] [Related]

  • 36. Protective effects of mineralocorticoid receptor blockade against neuropathy in experimental diabetic rats.
    Takata H, Takeda Y, Zhu A, Cheng Y, Yoneda T, Demura M, Yagi K, Karashima S, Yamagishi M.
    Diabetes Obes Metab; 2012 Feb 28; 14(2):155-62. PubMed ID: 21951301
    [Abstract] [Full Text] [Related]

  • 37. Angiotensin converting enzyme inhibitor suppresses glomerular transforming growth factor beta receptor expression in experimental diabetes in rats.
    Hill C, Logan A, Smith C, Grønbaek H, Flyvbjerg A.
    Diabetologia; 2001 Apr 28; 44(4):495-500. PubMed ID: 11357481
    [Abstract] [Full Text] [Related]

  • 38. Effect of combination therapy with a calcium channel blocker and an angiotensin-converting enzyme inhibitor on renal hypertrophy and urinary albumin excretion in diabetic rats.
    Nielsen B, Grønbaek H, Osterby R, Flyvbjerg A.
    Exp Diabesity Res; 2003 Apr 28; 4(3):191-9. PubMed ID: 15061647
    [Abstract] [Full Text] [Related]

  • 39. Effect of angiotensin-converting enzyme inhibition and angiotensin II type 1 receptor blockade on streptozotocin-induced diabetic nephropathy.
    Sen S, Kanter M, Ustundag S, Aktas C, Dogutan H, Yalcin O.
    Ren Fail; 2008 Apr 28; 30(10):1023-33. PubMed ID: 19016156
    [Abstract] [Full Text] [Related]

  • 40. Renoprotective effects of (+)-catechin in streptozotocin-induced diabetic rat model.
    Chennasamudram SP, Kudugunti S, Boreddy PR, Moridani MY, Vasylyeva TL.
    Nutr Res; 2012 May 28; 32(5):347-56. PubMed ID: 22652374
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 19.